CWBR Cohbar Anti-aging Stock Upside Potential
If you didn`t bought the stock at my first signal, now you can have a second chance, but 14% more expensive:
I think anti-aging stocks will be the next big thing of this decade.
Top Institutional Holders:
Blackrock Inc . 1,179,131 shares on Jun 29, 2020 worth 1,827,653 usd
Vanguard Group, Inc. 971,649 shares on Jun 29, 2020 worth 1,506,055 usd
Millennium Management LLC 362,116 shares on Jun 29, 2020 561,279 usd
On 9/17/2020 Roth Capital brokerage Initiated Coverage rating Buy with a target of $8.00.
Only 58Mil market cap
Chief Executive Officer, Steven Engle, will present a company update at the BIO Investor Forum, being held virtually on October 13-15, 2020.
Cohbar develops treatments that have widespread potential to target diseases related to aging and metabolic dysfunction, such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular diseases and central nervous system conditions.
In May, the company initiated testing of CB5064 analogs that interact with the apelin receptor in preclinical models of ARDS to assess their potential as therapeutics for COVID-19 associated ARDS.
Chief Executive Officer will be a participant on the panel titled “Emerging Companies” at the Targeting Metabesity Conference, being held virtually on October 12-15, 2020.
If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
I think anti-aging stocks will be the next big thing of this decade.
Top Institutional Holders:
Blackrock Inc . 1,179,131 shares on Jun 29, 2020 worth 1,827,653 usd
Vanguard Group, Inc. 971,649 shares on Jun 29, 2020 worth 1,506,055 usd
Millennium Management LLC 362,116 shares on Jun 29, 2020 561,279 usd
On 9/17/2020 Roth Capital brokerage Initiated Coverage rating Buy with a target of $8.00.
Only 58Mil market cap
Chief Executive Officer, Steven Engle, will present a company update at the BIO Investor Forum, being held virtually on October 13-15, 2020.
Cohbar develops treatments that have widespread potential to target diseases related to aging and metabolic dysfunction, such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular diseases and central nervous system conditions.
In May, the company initiated testing of CB5064 analogs that interact with the apelin receptor in preclinical models of ARDS to assess their potential as therapeutics for COVID-19 associated ARDS.
Chief Executive Officer will be a participant on the panel titled “Emerging Companies” at the Targeting Metabesity Conference, being held virtually on October 12-15, 2020.
If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.